Statins as a newly recognized type of immunomodulator

By B. Kwak, F. Mulhaupt, S. Myit, F. Mach. Nature Medicine, 2000

1,474 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hepatology, Immunology

View Paper: https://www.semanticscholar.org/paper/953ddd7cb7a929e21f63451882ad7d8e265d4c73

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. B. K. Pedersen
2. J. Towbin

In Immunology

1. B. K. Pedersen
2. S. Bensinger
3. A. Tedgui
4. P. Tontonoz
5. Z. Mallat
6. E. Janssen
7. R. Medzhitov

Citations in the corpus

• Age-related inflammatory cytokines and disease. (2003, background): “Evidence from in vivo [155–161] and in vitro [162,163] experiments has shown that statin exerts several nonlipid effects, most of which are immunomodulatory [157].”
• LXR signaling couples sterol metabolism to proliferation in the acquired immune response (2008, background): “Indeed, much of the immunomodulatory effects of statins have been attributed to the biology of these products (Kwak et al., 2000; Weitz-Schmidt et al., 2001).”
• The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. (2010, background): “, dendritic cells or B cell lymphocytes).(211) Studies with mRNA revealed that the specific mechanism of inhibition of MHC-II induction by statins is due to the selective repression of promoter IV on the MHC-II transactivator (CIITA) gene.”
• Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. (2008, background): “Indeed, the inhibitory effect of statins on MHC II expression is reversed by mevalonate and GGPP but not squalene (Figure 1), suggesting the involvement of small GTPases as the underlying mechanism [92].”
• Cytokines in atherosclerosis: pathogenic and regulatory pathways. (2006, background): “Interestingly, statins, which are believed to exert beneficial effects in cardiovascular disease beyond cholesterol lowering (350), have been reported to inhibit Th1-mediated disease and to block activation of STAT4 (386, 492, 778) and induction of major histocompatibilty complex (MHC)-II expression”